Safety and tolerability of anticonvulsant medication in bipolar disorder

Bibliography

• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 2007;64(5):543-52
   PubMed Web of Science ®Google Scholar
• Runge C, Grunze H. Jährliche krankheitskosten bipolarer störungen in deutschland. Nervenarzt 2004;75(9):896-903
   PubMed Web of Science ®Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: Findings from the global burden of disease study 2010. Lancet 2013;382(9904):1575-86
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. Patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58(1):85-91
   PubMed Web of Science ®Google Scholar
• Hayes J, Prah P, Nazareth I, et al. Prescribing trends in bipolar disorder: Cohort study in the United Kingdom thin primary care database 1995-2009. PLoS One 2011;6(12):e28725
   PubMed Web of Science ®Google Scholar
• Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program amsp. BMC Psychiatry 2012;12(153
   Google Scholar
• Goodwin GM; Consensus Group of the British Association for P. Evidence-based guidelines for treating bipolar disorder: Revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23(4):346-88
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. Disorders WTFoTGfB: The World Federation of Societies Of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14(3):154-219
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord 2013;15(1):1-44
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159(6):1011-17
   PubMed Web of Science ®Google Scholar
• Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. Am J Psychiatry 2003;160(7):1263-71
   PubMed Web of Science ®Google Scholar
• Grunze H, Grunze A, Born C. Polypharmazie in der behandlung bipolarer störungen. In: Messer T, Schmauss M, editors. Polypharmazie in der behandlung psychischer erkrankungen. Springer; Wien-New York: 2015. p. 81-102
   Google Scholar
• Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in Bipolar I disorder (balance): A randomised open-label trial. Lancet 2010;375(9712):385-95
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with Bipolar I disorder. Divalproex maintenance study group. Arch Gen Psychiatry 2000;57:481-9
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with Bipolar I disorder. Arch Gen Psychiatry 2003;60(4):392-400
   PubMed Web of Science ®Google Scholar
• Calabrese J, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with Bipolar I disorder. J Clin Psychiatry 2003;64(1013):1024
   Google Scholar
• Landmark CJ, Johannessen SI. Safety aspects of antiepileptic drugs--focus on pharmacovigilance. Pharmacoepidemiol Drug Saf 2012;21(1):11-20
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11(2):81-109
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders. Update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14(3):154-219
   PubMed Web of Science ®Google Scholar
• Lambert PA, Venaud G. Utilisation de valpromide en therapeutique psychiatrique. Encephale 1966;8:367-73
   Google Scholar
• Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991;48(1):62-8
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The depakote mania study group. JAMA 1994;271(12):918-24
   PubMed Web of Science ®Google Scholar
• Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006;67(10):1501-10
   PubMed Web of Science ®Google Scholar
• Lemoine P, Fondarai J, Faivre T. Valpromide increases amplitude of heart rate circadian rhythm in remitted bipolar and unipolar disorders. A placebo-controlled study. Eur Psychiatry 2000;15(7):424-32
   PubMed Web of Science ®Google Scholar
• McElroy SL, Martens BE, Creech RS, et al. Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania. J Clin Psychiatry 2010;71(5):557-65
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Baker JD, Wozniak P, et al. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry 2003;64(7):841-6
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: A randomized, 12-week, double-blind study. J Clin Psychiatry 2008;69(11):1776-89
   PubMed Web of Science ®Google Scholar
• Houston JP, Tohen M, Degenhardt EK, et al. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: A double-blind, placebo-controlled study. J Clin Psychiatry 2009;70(11):1540-7
   PubMed Web of Science ®Google Scholar
• Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: A placebo-controlled study. J Affect Disord 2005;85(3):259-66
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: A preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007;68(12):1840-4
   PubMed Web of Science ®Google Scholar
• Muzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: A double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2011;72(6):813-19
   PubMed Web of Science ®Google Scholar
• Sachs G, Collins MA, Altshuler L, et al. Divalproex sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus & Proceedings Summary 2002
   Google Scholar
• Smith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis. J Affect Disord 2010;122(1-2):1-9
   PubMed Web of Science ®Google Scholar
• Bowden CL, Singh V, Weisler R, et al. Lamotrigine vs Lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand 2012;126(5):342-50
   PubMed Web of Science ®Google Scholar
• Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: A 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71(2):130-7
   PubMed Web of Science ®Google Scholar
• Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: A multicenter, double-blind, randomized study. Bipolar Disord 2011;13(2):133-44
   PubMed Web of Science ®Google Scholar
• Investigators B, collaborators. Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial. Lancet 2010;375(9712):385-95
   PubMed Web of Science ®Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Cosmetic side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2015;42:129-37
   PubMed Web of Science ®Google Scholar
• Conley EL, Coley KC, Pollock BG, et al. Prevalence and risk of thrombocytopenia with valproic acid: Experience at a psychiatric teaching hospital. Pharmacotherapy 2001;21(11):1325-30
   PubMed Web of Science ®Google Scholar
• Ristic AJ, Vojvodic N, Jankovic S, et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: A study of 364 patients with different types of epilepsy. Epilepsia 2006;47(12):2183-5
   PubMed Web of Science ®Google Scholar
• Raja M, Azzoni A. Valproate-induced hyperammonaemia. J Clin Psychopharmacol 2002;22(6):631-3
   PubMed Web of Science ®Google Scholar
• Schmidt D. Adverse effects of valproate. Epilepsia 1984;25(Suppl 1):44-9
   Web of Science ®Google Scholar
• Bryant AEIII, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. Experience since 1986. Neurology 1996;46(2):465-9
   PubMed Web of Science ®Google Scholar
• Hynynen J, Komulainen T, Tukiainen E, et al. Acute liver failure after valproate exposure in patients with polg1 mutations and the prognosis after liver transplantation. Liver Transpl 2014;20(11):1402-12
   PubMed Web of Science ®Google Scholar
• Asconape JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia 1993;34(1):177-83
   PubMed Web of Science ®Google Scholar
• Krivoy N, Taer M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf 2006;1(3):289-99
   PubMedGoogle Scholar
• Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand Suppl 2005;426:13-20
   PubMedGoogle Scholar
• Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004;145(2):799-808
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Sharma V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009;26(3):281-94
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360(16):1597-605
   PubMed Web of Science ®Google Scholar
• Baker GA, Bromley RL, Briggs M, et al. Iq at 6 years after in utero exposure to antiepileptic drugs: A controlled cohort study. Neurology 2015;84(4):382-90
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: An observational study. Neurology 2015. [Epub ahead of print]
   Google Scholar
• Prac recommends strengthening the restrictions on the use of valproate in women and girls. Press Release 2014;2014
   Google Scholar
• Tomson T. Commentary: Valproate in the treatment of epilepsy in women and girls: The need for recommendations. Epilepsia 2015;56(7):1004-5
   PubMed Web of Science ®Google Scholar
• Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015;56(7):1006-19
   PubMed Web of Science ®Google Scholar
• Kowatch RA, Scheffer RE, Monroe E, et al. Placebo-controlled trial of valproic acid versus risperidone in children 3-7 years of age with bipolar i disorder. J Child Adolesc Psychopharmacol 2015;25(4):306-13
   PubMed Web of Science ®Google Scholar
• Wagner KD, Redden L, Kowatch RA, et al. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 2009;48(5):519-32
   PubMed Web of Science ®Google Scholar
• Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study. Psychopharmacology (Berl) 1979;66(3):211-17
   PubMed Web of Science ®Google Scholar
• Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65(4):478-84
   PubMed Web of Science ®Google Scholar
• Grunze HC. Anticonvulsants in bipolar disorder. J Ment Health 2010;19(2):127-41
   PubMed Web of Science ®Google Scholar
• Weisler RH, Keck PEJr, Swann AC, et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder. A multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005;66(3):323-30
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Kang WH, Tan QR, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007;41(3-4):360-9
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11(2):81-109
   PubMed Web of Science ®Google Scholar
• Hartong EG, Moleman P, Hoogduin CA, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003;64(2):144-51
   PubMed Web of Science ®Google Scholar
• Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders–a randomised study. J Affect Disord 1997;43(2):151-61
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of stevens-johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64(7):1134-8
   PubMed Web of Science ®Google Scholar
• Kaniwa N, Saito Y. The risk of cutaneous adverse reactions among patients with the HLA-A• 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: A perspective review. Ther Adv Drug Saf 2013;4(6):246-53
   Google Scholar
• Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005;165(8):869-74
   PubMed Web of Science ®Google Scholar
• Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002;63(Suppl 4):42-55
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the eurap epilepsy and pregnancy registry. Lancet Neurol 2011;10(7):609-17
   PubMed Web of Science ®Google Scholar
• Reddy DS. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol 2010;3(2):183-92
   PubMedGoogle Scholar
• Findling RL, Ginsberg LD. The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. Neuropsychiatr Dis Treat 2014;10:1589-97
   PubMed Web of Science ®Google Scholar
• Trinka E, Marson AG, Van Paesschen W, et al. KOMET: An unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013;84(10):1138-47
   PubMed Web of Science ®Google Scholar
• Werhahn KJ, Klimpe S, Balkaya S, et al. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: A one-year observational study. Seizure 2011;20(4):305-11
   PubMed Web of Science ®Google Scholar
• Fenn HH, Sommer BR, Ketter TA, Alldredge B. Safety and tolerability of mood-stabilising anticonvulsants in the elderly. Expert Opin Drug Saf 2006;5(3):401-16
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: A review of its use in bipolar disorder. Drugs 2003;63(19):2029-50
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 study group. J Clin Psychiatry 1999;60(2):79-88
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008;10(2):323-33
   PubMed Web of Science ®Google Scholar
• van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(2):223-31
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 study group. J Clin Psychiatry 2000;61(11):841-50
   PubMed Web of Science ®Google Scholar
• Maina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: A randomized, single-blind, pilot study. J Clin Psychiatry 2008;69(4):609-16
   PubMed Web of Science ®Google Scholar
• Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs Lamotrigine in the 6-month treatment of bipolar i depression. Int J Neuropsychopharmacol 2009;12(6):773-82
   PubMed Web of Science ®Google Scholar
• Kemp DE, Gao K, Fein EB, et al. Lamotrigine as add-on treatment to lithium and divalproex: Lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder. Bipolar Disord 2012;14(7):780-9
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65(3):432-41
   PubMed Web of Science ®Google Scholar
• Bowden CL, Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opin Pharmacother 2012;13(17):2565-71
   PubMed Web of Science ®Google Scholar
• Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: Evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 2005;25(4):342-8
   PubMed Web of Science ®Google Scholar
• Simms KM, Kortepeter C, Avigan M. Lamotrigine and aseptic meningitis. Neurology 2012;78(12):921-7
   PubMed Web of Science ®Google Scholar
• Statistical review and evaluation: Antiepileptic drugs and suicidality. Press Release 2008) 2008; Available from: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf
   Google Scholar
• Fountoulakis KN, Gonda X, Samara M, et al. Antiepileptic drugs and suicidality. J Psychopharmacol 2012;26(11):1401-7
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009;66(12):1354-60
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the eurap epilepsy and pregnancy registry. Lancet Neurol 2011;10(7):609-17
   PubMed Web of Science ®Google Scholar
• Viguera AC, Koukopoulos A, Muzina DJ, Baldessarini RJ. Teratogenicity and anticonvulsants: Lessons from neurology to psychiatry. J Clin Psychiatry 2007;68(Suppl 9):29-33
   PubMed Web of Science ®Google Scholar
• Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001;47(1-2):151-4
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Ueberall MA, Siemes H, et al. The LAM-SAFE study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure 2005;14(8):597-605
   PubMed Web of Science ®Google Scholar
• Anderson GD. Children versus adults: Pharmacokinetic and adverse-effect differences. Epilepsia 2002;43(Suppl 3):53-9
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37(1):81-7
   PubMed Web of Science ®Google Scholar
• Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: A randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64(11):1868-73
   PubMed Web of Science ®Google Scholar
• Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8(1):15-27
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin bipolar disorder study group. Bipolar Disord 2000;2(3 Pt 2):249-55
   PubMed Web of Science ®Google Scholar
• Vasudev A, Macritchie K, Watson S, et al. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2008;1:CD005171
   PubMed Web of Science ®Google Scholar
• Grunze H, Kotlik E, Costa R, et al. Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase ii clinical studies in patients with bipolar disorder I. J Affect Disord 2015;174:70-82
   PubMed Web of Science ®Google Scholar
• Van AT, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review. Epilepsia 1994;35(1):181-8
   PubMed Web of Science ®Google Scholar
• Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998;50:245-51
   PubMed Web of Science ®Google Scholar
• Vieta E, Sanchez-Moreno J, Goikolea JM, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004;24(4):374-8
   PubMed Web of Science ®Google Scholar
• McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025-33
   PubMed Web of Science ®Google Scholar
• Jones MW. Topiramate–safety and tolerability. Can J Neurol Sci 1998;25(3):S13-15
   PubMed Web of Science ®Google Scholar
• Lamoure J, Stovel J, Chandarana P. Probable topiramate-induced hemiparesis. Can J Hosp Pharm 2010;63(3):233-5
   PubMedGoogle Scholar
• Vieta E, Manuel GJ, Martinez-Aran A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006;67(3):473-7
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85-116
   PubMed Web of Science ®Google Scholar
• Grunze H, Langosch J, Born C, et al. Levetiracetam in the treatment of acute mania: An open add-on study with an on-off-on design. J Clin Psychiatry 2003;64(7):781-4
   PubMed Web of Science ®Google Scholar
• Krüger S, Sarkar R, Pietsch R, et al. Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study. Psychopharmacology (Berl) 2008;198(2):297-9
   PubMed Web of Science ®Google Scholar
• Post RM, Altshuler LL, Frye MA, et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005;66(3):370-4
   PubMed Web of Science ®Google Scholar
• Saricicek A, Maloney K, Muralidharan A, et al. Levetiracetam in the management of bipolar depression. A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(6):744-50
   PubMed Web of Science ®Google Scholar
• McElroy SL, Suppes T, Keck PEJr, et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: A prospective trial. J Clin Psychiatry 2005;66(5):617-24
   PubMed Web of Science ®Google Scholar
• Wilson MS, Findling RL. Zonisamide for bipolar depression. Expert Opin Pharmacother 2007;8(1):111-13
   PubMed Web of Science ®Google Scholar
• Amann B, Sterr A, Vieta E, et al. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. J Clin Psychopharmacol 2006;26(5):534-6
   PubMed Web of Science ®Google Scholar
• Clark S, Antell A, Kaufman K. New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf 2015;6(1):15-19
   PubMedGoogle Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (aeds)--part 2. Pharmacokinetic and pharmacodynamic interactions between aeds and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet 2013;52(12):1045-61
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ilae commission on therapeutic strategies. Epilepsia 2008;49(7):1239-76
   PubMed Web of Science ®Google Scholar